XTX Topco Ltd Takes $526,000 Position in AtriCure, Inc. (NASDAQ:ATRC)

XTX Topco Ltd purchased a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 16,301 shares of the medical device company's stock, valued at approximately $526,000.

A number of other institutional investors have also bought and sold shares of the company. Invesco Ltd. boosted its position in AtriCure by 0.8% during the fourth quarter. Invesco Ltd. now owns 43,647 shares of the medical device company's stock valued at $1,334,000 after acquiring an additional 334 shares during the last quarter. State of Wyoming boosted its position in AtriCure by 21.9% during the fourth quarter. State of Wyoming now owns 2,481 shares of the medical device company's stock valued at $76,000 after acquiring an additional 446 shares during the last quarter. LPL Financial LLC boosted its position in AtriCure by 5.4% during the fourth quarter. LPL Financial LLC now owns 11,465 shares of the medical device company's stock valued at $350,000 after acquiring an additional 584 shares during the last quarter. First Horizon Advisors Inc. boosted its position in shares of AtriCure by 135.3% during the 1st quarter. First Horizon Advisors Inc. now owns 1,447 shares of the medical device company's stock worth $47,000 after purchasing an additional 832 shares in the last quarter. Finally, Parallel Advisors LLC boosted its position in shares of AtriCure by 13.0% during the 1st quarter. Parallel Advisors LLC now owns 7,229 shares of the medical device company's stock worth $233,000 after purchasing an additional 833 shares in the last quarter. Institutional investors own 99.11% of the company's stock.

Insider Buying and Selling at AtriCure

In other news, insider Vinayak Doraiswamy sold 2,500 shares of AtriCure stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $36.58, for a total transaction of $91,450.00. Following the completion of the sale, the insider directly owned 71,872 shares of the company's stock, valued at approximately $2,629,077.76. The trade was a 3.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Regina E. Groves sold 2,452 shares of AtriCure stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $36.82, for a total transaction of $90,282.64. Following the sale, the director directly owned 33,715 shares of the company's stock, valued at $1,241,386.30. This represents a 6.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 7,452 shares of company stock valued at $265,333. Insiders own 3.50% of the company's stock.

AtriCure Price Performance

NASDAQ:ATRC traded down $0.59 during trading hours on Friday, hitting $35.31. The stock had a trading volume of 398,416 shares, compared to its average volume of 712,018. The company has a 50 day simple moving average of $32.62 and a two-hundred day simple moving average of $34.21. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.94 and a quick ratio of 2.83. AtriCure, Inc. has a one year low of $20.44 and a one year high of $43.11. The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of -45.86 and a beta of 1.61.

AtriCure (NASDAQ:ATRC - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The medical device company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.13. AtriCure had a negative net margin of 7.27% and a negative return on equity of 4.20%. The firm had revenue of $136.14 million during the quarter, compared to the consensus estimate of $130.17 million. During the same period last year, the firm earned ($0.17) EPS. The business's quarterly revenue was up 17.1% compared to the same quarter last year. Research analysts forecast that AtriCure, Inc. will post -0.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ATRC. BTIG Research set a $54.00 price objective on shares of AtriCure in a research report on Wednesday, July 30th. JMP Securities reissued a "market outperform" rating and set a $60.00 price objective on shares of AtriCure in a research report on Wednesday, April 30th. Needham & Company LLC increased their price objective on shares of AtriCure from $44.00 to $45.00 and gave the stock a "buy" rating in a research report on Wednesday, July 30th. UBS Group cut their price objective on shares of AtriCure from $60.00 to $58.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Finally, Wall Street Zen upgraded shares of AtriCure from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $50.89.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.